Evidence map›Paper›PMID 36380228›Full record

ArticleScientific reports2022

Characterization of alternative mRNA splicing in cultured cell populations representing progressive stages of human fetal kidney development.

Yishay Wineberg, Itamar Kanter, Nissim Ben-Haim, Naomi Pode-Shakked, Efrat Bucris, Tali Hana Bar-Lev, Sarit Oriel, Harel Reinus, Yishai Yehuda, Rotem Gershon and 5 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Characterization of Alternative Splicing in High-Risk Wilms' Tumors.International journal of molecular sciences · 2024
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Yishay Wineberg *Department of Bioengineering and Bar-Ilan Institute of Nanotechnology and Advanced Materials (BINA), Bar-Ilan University, 52900, Ramat Gan, Israel.
Itamar Kanter *Department of Bioengineering and Bar-Ilan Institute of Nanotechnology and Advanced Materials (BINA), Bar-Ilan University, 52900, Ramat Gan, Israel.
Nissim Ben-Haim *Department of Bioengineering and Bar-Ilan Institute of Nanotechnology and Advanced Materials (BINA), Bar-Ilan University, 52900, Ramat Gan, Israel.
Naomi Pode-Shakked *Pediatric Stem Cell Research Institute, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, 52621, Tel-Hashomer, Israel.ORCID 0000-0001-9179-6355
Efrat BucrisDepartment of Bioengineering and Bar-Ilan Institute of Nanotechnology and Advanced Materials (BINA), Bar-Ilan University, 52900, Ramat Gan, Israel.
Tali Hana Bar-LevDepartment of Bioengineering and Bar-Ilan Institute of Nanotechnology and Advanced Materials (BINA), Bar-Ilan University, 52900, Ramat Gan, Israel.
Sarit OrielDepartment of Bioengineering and Bar-Ilan Institute of Nanotechnology and Advanced Materials (BINA), Bar-Ilan University, 52900, Ramat Gan, Israel.
Harel ReinusDepartment of Bioengineering and Bar-Ilan Institute of Nanotechnology and Advanced Materials (BINA), Bar-Ilan University, 52900, Ramat Gan, Israel.ORCID 0000-0001-6119-7466
Yishai YehudaDepartment of Bioengineering and Bar-Ilan Institute of Nanotechnology and Advanced Materials (BINA), Bar-Ilan University, 52900, Ramat Gan, Israel.
Rotem GershonPediatric Stem Cell Research Institute, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, 52621, Tel-Hashomer, Israel.
Rachel ShukrunPediatric Stem Cell Research Institute, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, 52621, Tel-Hashomer, Israel.
Dekel Dov Bar-LevPediatric Stem Cell Research Institute, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, 52621, Tel-Hashomer, Israel.
Achia UrbachThe Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, 52900, Ramat-Gan, Israel.
Benjamin DekelPediatric Stem Cell Research Institute, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, 52621, Tel-Hashomer, Israel.
Tomer KaliskyDepartment of Bioengineering and Bar-Ilan Institute of Nanotechnology and Advanced Materials (BINA), Bar-Ilan University, 52900, Ramat Gan, Israel. tomer.kalisky@biu.ac.il.ORCID 0000-0003-4733-262X
Bar-Ilan University · ILTel Aviv University · ILSheba Medical Center · IL

Funding

Marie Curie International Reintegration 618592the ICRF 19-101-PGthe Israel Cancer Association 20150911the Israel Ministry of Health 3-10146The Israel Science Foundation 1634/13The Israel Science Foundation 1902/12The Israel Science Foundation 2017/13The Israel Scientific Foundation 2071/17The Israel Scientific Foundation 910/11
6 · The paper itself

Abstract

Nephrons are the functional units of the kidney. During kidney development, cells from the cap mesenchyme-a transient kidney-specific progenitor state-undergo a mesenchymal to epithelial transition (MET) and subsequently differentiate into the various epithelial cell types that create the tubular structures of the nephron. Faults in this transition can lead to a pediatric malignancy of the kidney called Wilms' tumor that mimics normal kidney development. While human kidney development has been characterized at the gene expression level, a comprehensive characterization of alternative splicing is lacking. Therefore, in this study, we performed RNA sequencing on cell populations representing early, intermediate, and late developmental stages of the human fetal kidney, as well as three blastemal-predominant Wilms' tumor patient-derived xenografts. Using this newly generated RNAseq data, we identified a set of transcripts that are alternatively spliced between the different developmental stages. Moreover, we found that cells from the earliest developmental stage have a mesenchymal splice-isoform profile that is similar to that of blastemal-predominant Wilms' tumor xenografts. RNA binding motif enrichment analysis suggests that the mRNA binding proteins ESRP1, ESRP2, RBFOX2, and QKI regulate alternative mRNA splicing during human kidney development. These findings illuminate new molecular mechanisms involved in human kidney development and pediatric kidney cancer.

Indexed as

Kidney NeoplasmsWilms TumorAlternative SplicingCells, CulturedChildHumansKidneyRepressor ProteinsRNA, MessengerRNA Splicing FactorsRBFOX2 protein, humanRepressor ProteinsRNA, MessengerRNA Splicing Factors

Identifiers

PMID36380228
PMCPMC9666651
OpenAlexW4309192281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.